EUCTR2005-000487-11-DK进行中（未招募）不适用
A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement - RESOLVE
ovartis Pharma Service AG0 个研究点目标入组 150 人开始时间: 2005年8月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patients >18 years of age who have signed an informed consent
- •2.Patients with type 1 or type 2 diabetes mellitus diagnosed =24 months prior to screening and a documented history of stable HbA1c =6.5% and =9.5% at the time of screening (stable HbA1c values are defined as those that do not differ at monthly assessments by more than 0.5% HbA1c). Any one of the following will be considered to be sufficient evidence that diabetes is present
- •Current regular use of insulin for the treatment of diabetes
- •Current regular use of oral antihyperglycemia agents for the treatment of diabetes
- •Documented diabetes by ADA and/or WHO criteria
- •3.Patients with diabetic macular edema with center involvement in at least one eye, including those with focal or diffuse DME, as demonstrated with stereoscopic fundus photography, fluorescein angiography and optical coherence tomography within 28 days of the baseline treatment. For this eye to achieve eligibility statue it must fulfill the following three criteria at Visit 1:
- •The central macular thickness must be =300 µm in the center subfield, as assessed by OCT and confirmed by the central reading center;
- •BCVA score between 69 and 39 letters, inclusively, using ETDRS-like visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/40 to 20/160);
- •Decrease in vision is due to foveal thickening from DME and not due to other causes, in the opinion of the investigator.
- •4.Patients with DME without previous laser photocoagulation or who have been treated at least 6 months preceding Day 1 with mild focal laser photocoagulation consisting of no more than 30 laser burns that are at least 500 µm from the center of the fovea will be allowed to enter the study.
- •5.Only one eye will be selected for study treatment (study eye). If both eyes are eligible, the one with the worse visual acuity, as assessed at Visit 1, will be selected for study treatment unless, based on medical reasons, the investigator deems the other eye the more appropriate candidate for study treatment. The medical reason for selecting the study eye having the better visual acuity must be described in the eCRF
- •6.Patients for whom, in the opinion of the investigator, laser photocoagulation in the study eye can be withheld for at least 3 months after randomization
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.A condition that in the opinion of the investigator would preclude a patient’s participation in the study, e.g., unstable medical status including glycemic control and blood pressure. Patients in poor glycemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4 months should not be enrolled. Patients with hypertension for whom a change in antihypertensive treatment was initiated within 2 months preceding Day 1 should not be enrolled unless blood pressure is maintained for at least 1 month prior Day 1 below 150/95 mm Hg by antihypertensive treatment
- •2.History of systemic (e.g., oral, IV, IM, epidural, bursal) corticosteroids within 4 months prior to randomization or topical, rectal, or inhaled corticosteroids in current use more than 2 times per week
- •3.Panretinal grid or scatter laser photocoagulation or macular laser photocoagulation attempting to resolve macular edema in the study eye. This criterion may become void if results of interim analyses support the inclusion of patients whose study eye has undergone previous laser photocoagulation
- •4.Known duration of macular edema involving the center of more than 9 months
- •5.Proliferative diabetic retinopathy in the study eye, with the exception of tufts of neovascularization less than one disc area with no vitreous hemorrhage. Proliferative diabetic retinopathy in the study eye for which only focal, peripheral retinal areas were treated with photocoagulation with fewer than 30 laser burns performed at least 6 months preceding Day 1 is permitted
- •6.Area of retinal ischemia =500 µm and located =500 µm from the center of the macula of the study eye as assessed by fluorescein angiography at Visit 1 and confirmed by a central reading center
- •7.Any active infection involving ocular adnexa including infectious conjunctivitis, keratitis, scleritis, endophthalmitis, as well as idiopathic or autoimmune-associated uveitis in either eye
- •8.Cataract surgery in the study eye within the past 6 months, Yttrium-Aluminum-Garnet (YAG) laser capsulotomy within the past 6 months, or any intraocular surgery within the past 6 months preceding Day 1
- •9.Aphakia or absence of the posterior capsule in the study eye
- •10.History of uncontrolled glaucoma (defined as intraocular pressure =25 mm Hg despite treatment with anti-glaucoma medication) or low tension glaucoma in the study eye
- •11.Blood pressure: Systolic = 150 mmHg and/or Diastolic = 95 mmHg .If blood pressure is brought and maintained for at least 1 month prior Day 1 below 150/95 mm Hg by antihypertensive treatment, patient can become eligible
- •12.History of chronic renal failure requiring dialysis or kidney transplant
- •13.Pre-menopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization; use of oral contraceptives; barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel; an IUD; or contraceptive hormone implant or patch
- •14.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/ml)
- •15.Current treatment for active systemic infection
- •16.Use of anticoagulants during the study, e.g., coumadin, warfarin, heparin. The use of aspirin is not an exclusion
- •17.History of allergy to fluorescein, not amenable to treatment
研究者
相似试验
进行中（未招募）
不适用
A phase IIa, multi-center, randomized, double-blind, vehicle-controlled study to determine antipsoriatic efficacy and safety of topical CEP-701 (lestaurtinib) cream formulations in patients with psoriasis vulgaris - POC PsoriasisChronic plaque type psoriasis of mild to moderate severity, at least one plaque with a treatment area of approximately 25 - 50 cm2MedDRA version: 9.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisEUCTR2008-002317-40-DEPerrigo Israel Pharmaceuticals Ltd.80
进行中（未招募）
不适用
A phase IIa, multi-center, randomized, double-blind study to evaluate the anti-mycotic and anti-inflammatory efficacy of topical combinational product LAS 41003 versus corresponding mono-substances in patients with candida infections in intertriginous areas at the trunk - Candida intertriginosaEUCTR2009-016627-56-DEAlmirall Hermal GmbH
进行中（未招募）
不适用
A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a new regimen and new formulation of MCI-186 in subjects with acute ischemic strokeAcute ischemic strokeEUCTR2008-003397-17-NLMitsubishi Tanabe Pharma Corporation
进行中（未招募）
不适用
A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a new regimen and new formulation of MCI-186 in subjects with acute ischemic strokeAcute ischemic strokeMedDRA version: 9.1Level: LLTClassification code 10055221Term: Ischemic strokeEUCTR2008-003397-17-GBMitsubishi Tanabe Pharma Corporation36
已完成
2 期
A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a new regimen and new formulation of MCI-186 in subjects with acute ischemic strokeAcute Ischemic Stroke (AIS) - stroke10011954NL-OMON35656Mitsubishi Pharma Corporation12